West Pharmaceutical Services (WST) Stock Forecast & Price Target
WST Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to West Pharmaceutical Services in the past 3 months
WST Stock 12 Month Forecast
Average Price Target
MXN 9,028.83▲(70.36% Upside)Based on 6 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is MXN 9,028.83 with a high forecast of MXN 9,441.09 and a low forecast of MXN 7,552.87. The average price target represents a 70.36% change from the last price of MXN 5,300.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 9.44K
AverageMXN 9.03K
LowMXN 7.55K
Highest Price TargetHighestMXN 9,441.09Average Price TargetMXN 9,028.83Lowest Price TargetLowestMXN 7,552.87
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | Barclays | MXN 8,308.16→MXN 9,441.09 | buy | 78.13%Upside | Reiterated | 10/30/26 | ||
| Joanne Wuensch | Citi | MXN 7,779.46→MXN 9,327.79 | buy | 76.00%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | UBS | MXN 8,213.75→MXN 9,346.68 | buy | 76.35%Upside | Reiterated | 10/30/26 | ||
| Brendan Smith | TD Cowen | MXN 7,930.51→MXN 9,441.09 | buy | 78.13%Upside | Reiterated | 10/30/26 | ||
| Daniel Markowitz CFA | Evercore ISI | MXN 8,308.16→MXN 9,063.44 | buy | 71.01%Upside | Reiterated | 10/30/26 | ||
| Kallum Titchmarsh | Morgan Stanley | MXN 6,891.99→MXN 7,552.87 | buy | 42.51%Upside | Upgraded | 09/22/26 | ||
| Michael Ryskin | Bank of America Securities | MXN 7,741.69 | buy | 46.07%Upside | Reiterated | 07/24/26 | ||
| Matt Larew | William Blair | ― | buy | ― | Reiterated | 07/23/26 | ||
| Curtis Moiles | Exane BNP Paribas | MXN 8,440.33 | buy | 59.25%Upside | Initiated | 07/13/26 | ||
| Paul Knight | KeyBanc | MXN 6,608.76→MXN 7,364.05 | buy | 38.94%Upside | Reiterated | 07/02/26 | ||
| Michael Polark | Wolfe Research | MXN 7,080.82 | buy | 33.60%Upside | Assigned | 06/01/26 | ||
| Justin Bowers | Deutsche Bank | MXN 5,853.47→MXN 5,947.89 | buy | 12.22%Upside | Reiterated | 02/13/26 | ||
| Dan Leonard | RBC Capital | MXN 6,703.17→MXN 6,419.94 | buy | 21.13%Upside | Reiterated | 02/13/26 | ||
| David Windley | Jefferies | MXN 6,891.99→MXN 5,570.24 | buy | 5.10%Upside | Reiterated | 02/10/26 | ||
| Nico Chen | DBS | MXN 6,042.30 | buy | 14.01%Upside | Reiterated | 01/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | 10/30/26 | MXN 8,308.16→MXN 9,441.09 | buy | 78.13%Upside | Reiterated | Barclays | ||
| Joanne Wuensch | 10/30/26 | MXN 7,779.46→MXN 9,327.79 | buy | 76.00%Upside | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 10/30/26 | MXN 8,213.75→MXN 9,346.68 | buy | 76.35%Upside | Reiterated | UBS | ||
| Brendan Smith | 10/30/26 | MXN 7,930.51→MXN 9,441.09 | buy | 78.13%Upside | Reiterated | TD Cowen | ||
| Daniel Markowitz CFA | 10/30/26 | MXN 8,308.16→MXN 9,063.44 | buy | 71.01%Upside | Reiterated | Evercore ISI | ||
| Kallum Titchmarsh | 09/22/26 | MXN 6,891.99→MXN 7,552.87 | buy | 42.51%Upside | Upgraded | Morgan Stanley | ||
| Michael Ryskin | 07/24/26 | MXN 7,741.69 | buy | 46.07%Upside | Reiterated | Bank of America Securities | ||
| Matt Larew | 07/23/26 | ― | buy | ― | Reiterated | William Blair | ||
| Curtis Moiles | 07/13/26 | MXN 8,440.33 | buy | 59.25%Upside | Initiated | Exane BNP Paribas | ||
| Paul Knight | 07/02/26 | MXN 6,608.76→MXN 7,364.05 | buy | 38.94%Upside | Reiterated | KeyBanc | ||
| Michael Polark | 06/01/26 | MXN 7,080.82 | buy | 33.60%Upside | Assigned | Wolfe Research | ||
| Justin Bowers | 02/13/26 | MXN 5,853.47→MXN 5,947.89 | buy | 12.22%Upside | Reiterated | Deutsche Bank | ||
| Dan Leonard | 02/13/26 | MXN 6,703.17→MXN 6,419.94 | buy | 21.13%Upside | Reiterated | RBC Capital | ||
| David Windley | 02/10/26 | MXN 6,891.99→MXN 5,570.24 | buy | 5.10%Upside | Reiterated | Jefferies | ||
| Nico Chen | 01/28/26 | MXN 6,042.30 | buy | 14.01%Upside | Reiterated | DBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering West Pharmaceutical Services
3 Months
Success Rate8/10 ratings generated profit
80%
Average Return
+14.30%
Copying Matt Larew's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.30% per trade.
1 Year
Success Rate5/5 ratings generated profit
100%
Average Return
+37.40%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.40% per trade.
2 Years
Success Rate6/6 ratings generated profit
100%
Average Return
+61.45%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +61.45% per trade.
WST Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 11 | 17 | 14 | 13 | 10 |
| Hold | 8 | 5 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 19 | 22 | 16 | 15 | 11 |
In the current month, WST has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WST average Analyst price target in the past 3 months is 9,028.83.
WST Financial Forecast
HighMXN 43.59
ConsensusMXN 42.97
LowMXN 41.89
WST Earnings Forecast
Next quarter’s earnings estimate for WST is MXN 42.97 with a range of MXN 41.89 to MXN 43.59. The previous quarter’s EPS was MXN 49.97. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 15.8B
ConsensusMXN 15.5B
LowMXN 15.4B
WST Sales Forecast
Next quarter’s sales forecast for WST is MXN 15.52B with a range of MXN 15.42B to MXN 15.80B. The previous quarter’s sales results were MXN 16.43B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
WST Stock Forecast FAQ
What is MX:WST’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services’s 12-month average price target is Mex$9,028.83.
What is MX:WST’s upside potential, based on the analysts’ average price target?
West Pharmaceutical Services has 70.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is West Pharmaceutical Services a Buy, Sell or Hold?
West Pharmaceutical Services has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is West Pharmaceutical Services’s share price target?
The average share price target for West Pharmaceutical Services is Mex$9,028.83. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$9,441.09, and the lowest forecast is Mex$7,552.87. The average share price target represents a 70.36% increase from the current price of Mex$5,300.
What do analysts say about West Pharmaceutical Services?
West Pharmaceutical Services’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of West Pharmaceutical Services?
To buy shares of MX:WST, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.